Urgent.News

What's breaking now, across thousands of outlets.

World

#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity

MADRID — Pfizer is moving past its late-stage loss in non-small cell lung cancer, pointing to a post-hoc analysis of earlier-line patients who appear to benefit. Also on Sunday, BioNTech and Bristol Myers Squibb touted ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in World

More from Sunday 25 October →